https://www.selleckchem.com/pr....oducts/cwi1-2-hydroc
However, the compliance rate was low. Adherence to metformin XR was 52% (IQR42% to 61%) based on the remaining tablets in the container after 4months of intervention. None of the reported side effects were deemed to be related to the study treatment and no significant differences were observed between the metformin XR and the control group. Treatment with Metformin XR in participants admitted with stroke and with pre-diabetes is feasible and safe. Strategies are needed to improve adherence in future trials. Treatment with M
Like
Comment
Share
